Regeneron Pharmaceuticals (REGN)
$281.62 2.56 (0.90%)
19:59 EDT REGN Stock Quote Delayed 15 Minutes
Previous Close $281.62
Market Cap 29.84B
PE Ratio 22.82
Volume (Avg. Vol.) 617,100
Day's Range 279.47 - 287.00
52-Week Range 271.57 - 442.00
Dividend & Yield N/A (N/A)
REGN Stock Predictions, Articles, and Regeneron Pharmaceuticals News
- From InvestorPlace
- From the Web
When rumors start buzzing that the government may be about to intervene, then biotech stocks often get slammed...some fairly, and some not (as we’ll see).
Uncertainty is a constant risks for biotech stocks. Which ones matter? Some are down so much investors cannot ignore them now.
Biotech stocks have been looking rough lately, and these four names have been helping to lead the charge lower.
Trump says that Facebook and Alphabet should be sued, while Micron surged on earnings. Semiconductors got a big boost in the Nasdaq today as well.
Government is scrutinizing the drug development and approval process and creating uncertainties among biotech stocks. Time to buy?
Regeneron Pharmaceuticals earnings for the first quarter of 2019 have REGN stock falling on Tuesday due to poor results for the period.
While some companies are doing a good job closing their CEO-Worker wage gaps, these seven companies are not.
When drug companies fall out of favor, as now, I look first to companies with a method for drug discovery like Regeneron stock.
No company can guarantee its future, but here are some that are well-positioned to take advantage of current trends.
It might seem like an odd pairing, but WING and REGN stock have similar leadership qualities off and on the price chart.
The best stocks to buy at the bottom of a bear market are those you can see growing over the next three to five years.
Teva stock is now at yearly lows, a victim of negative macro news, falling stock markets, and year-end tax-loss selling.
Want to know the top stocks with strong balance sheets right now? Apple is one, but there are six others that are also impressive. Come read!
Biogen stock reaffirmed its dominance in MS and the neurosciences market. At a low P/E mutliple, investors should look at BIIB again.
Healthcare stocks recovered throughout 2018 but the recent correction in some big names is creating an entry point.
Thanks to advancing technologies and a generally positive economy, healthcare stocks are back in the limelight.
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!